https://pharminent.com/eli-lilly-acquires-ajax-therapeutics-for-first-in-class-jak2-inhibitor-in-myelofibrosis/ 2026-04-27T12:02:15Z Pharminent en Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis 2026-04-27T10:45:00Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-april-25-2026/ 2026-04-25T23:45:27Z Pharminent en Week in Review • INTELLIGENCE BRIEF • April 25, 2026 2026-04-25T23:45:24Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-april-24-2026/ 2026-04-25T21:29:27Z Pharminent en GLP-1 Competitive Market Digest • Weekly • April 24, 2026 2026-04-25T21:27:29Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-april-24-2026/ 2026-04-25T20:27:32Z Pharminent en Oncology Intelligence Digest • April 24, 2026 2026-04-25T20:27:29Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-april-22-2026/ 2026-04-25T20:24:47Z Pharminent en Manufacturing Intelligence • Weekly Digest • April 22, 2026 2026-04-25T20:24:43Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-april-22-2026/ 2026-04-25T20:22:59Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • April 22, 2026 2026-04-25T20:22:56Z Blog